Skip to content

Blood Products in Cardiac Surgery

The Use of Blood Products in Patients Undergoing Cardiac Surgery

Status
Completed
Phases
Unknown
Study type
Observational
Source
ClinicalTrials.gov
Registry ID
NCT02068755
Acronym
BiCS
Enrollment
31000
Registered
2014-02-21
Start date
2002-01-31
Completion date
2012-12-31
Last updated
2014-02-21

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Anemia, Renal Impairment, Thrombocytopenia

Keywords

anemia, renal impairment, thrombocytopenia, anticoagulation, Coronary bypass, Aortic valve surgery, Mitral valve surgery, red blood cell, platelet, fresh frozen plasma, octaplas

Brief summary

Blood transfusion is a common procedure essential for the treatment of patients undergoing cardiac surgery. Inappropriate transfusions, however, not only incur needless healthcare costs, but increase unnecessary risks due to transfusion reactions and infectious and immunomodulative causes. Safe and appropriate patient care requires evaluated blood component prescription practices. Practically all patients undergoing cardiac surgery in Finland have a blood product booking from the Finnish Red Cross Blood Service. This registry contains large volumes of transfusion-related information on all Finnish patients undergoing cardiac surgery in Finnish centers. Participating hospitals were scattered to all geographical areas in Finland and concentrated to the most populated regions. Data on the blood product use, laboratory findings one month pre-operatively and 12 months post-operatively were available. Finnish hospitals have been required to provide information on hospital visits for the Finnish National Research and Development Centre for Welfare and Health for healthcare planning purposes. We used in part the original data sent by hospitals to the Finnish Hospital Discharge Register (FHDR).

Detailed description

Registry includes * \>21 000 patients who underwent coronary bypass, * \>4500 patients with aortic valve replacement, * \>4000 mitral valve operation.

Interventions

None listed

Sponsors

Finnish Red Cross Blood Service
CollaboratorOTHER
Central Finland Hospital District
CollaboratorOTHER
Turku University Hospital
CollaboratorOTHER_GOV
Oulu University Hospital
CollaboratorOTHER
Tampere University Hospital
CollaboratorOTHER
Kuopio University Hospital
CollaboratorOTHER
Helsinki University Central Hospital
CollaboratorOTHER
Satakunta Central Hospital
CollaboratorOTHER
University of Turku
Lead SponsorOTHER

Study design

Observational model
COHORT
Time perspective
PROSPECTIVE

Eligibility

Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
No

Inclusion criteria

* Cardiac surgery performed in Finnish University and Central hospitals * Blood product booking for surgery

Exclusion criteria

\-

Design outcomes

Primary

MeasureTime frame
Octaplas12 months
Red blood cell infusions12 months
Platelet infusion12 months
Fresh frozen plasma12 months

Secondary

MeasureTime frame
All cause mortality12 months
myocardial infarction12 months
TIA/stroke/arterial embolism12
re-operation due to bleeding12 months

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026